For the Inventor, By the Inventor

Enter assignee name

Morris Plains, NJ, United States of America

Ibc Pharmaceuticals, Inc.

USPTO Granted Patents = 72

% Expired Patents = 9.7

CIPO Patents = 4

EPO Patents = 13

Forward Citations = 1,881

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

David M Goldenberg (69 out of 393 patents)

Chien-Hsing Chang (66 out of 140 patents)

Edmund A Rossi (52 out of 77 patents)

4. William John McBride (22 out of 85 patents)

5. Diane Rossi (11 out of 13 patents)

6. Chien Hsing Chang (4 out of 8 patents)

7. Hans J Hansen (3 out of 191 patents)

8. Rongxiu Li (3 out of 3 patents)

9. Donglin Liu (2 out of 5 patents)

10. Serengulam V Govindan (1 out of 112 patents)

11. Fernando Jose Rebelo Do Couto (1 out of 31 patents)

12. Roberto L Ceriani (1 out of 17 patents)

13. Jerry A Peterson (1 out of 1 patent)

14. William J Mcbride (0 patent)

15. Chien-Hsing Ken Chang (0 patent)

Core Competencies:

Bispecific Antibodies

Cytokines

DNL Technology

Immunoconjugates

Checkpoint Inhibitors

Combination Therapy

Immunotoxins

Trop-2

Anti-TNF-alpha

HIV Therapy

Multivalent Complexes

Cancer Vaccines

72 patents: Sort by Forward Citations

1. 10662252 - Disease therapy by inducing immune response to Trop-2 expressing cells (2020-05-26),

2. 10385139 - Murine, chimeric, humanized or human anti-TNF-alpha antibodies (2019-08-20),

3. 10308688 - T-cell redirecting bispecific antibodies for treatment of disease (2019-06-04),

4. 10280220 - Immunoconjugates with an intracellularly-cleavable linkage (2019-05-07),

5. 10245321 - Combination therapy for inducing immune response to disease (2019-04-02),

6. 10239938 - T-cell redirecting bispecific antibodies for treatment of disease (2019-03-26),

7. 10183992 - T-cell redirecting bispecific antibodies for treatment of disease (2019-01-22),

8. 10131712 - Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors (2018-11-20),

9. 10111954 - Combination therapy for inducing immune response to disease (2018-10-30),

10. 10022427 - Interferon lambda-antibody complexes (2018-07-17),

11. 9932413 - Murine, chimeric, humanized or human anti-IL-6 antibodies (2018-04-03),

12. 9931413 - Tetrameric cytokines with improved biological activity (2018-04-03),

13. 9879088 - Disease therapy by inducing immune response to Trop-2 expressing cells (2018-01-30),

14. 9872920 - PEGylation by the dock and lock (DNL) technique (2018-01-23),

15. 9862770 - Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors (2018-01-09),

IBC Pharmaceuticals, Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative therapies. With a strong focus on research and development, we strive to improve patients' lives by bringing advanced treatments to market. Our team of dedicated scientists and professionals work tirelessly to discover and develop novel drugs, with a particular emphasis on oncology and immunology. Continuous innovation, cutting-edge technologies, and a commitment to integrity are the foundations of our success.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

72 Patents

#3 in Morris Plains, NJ

#220 in New Jersey

#5,098 in US

#10,370 in the World

Morris Plains, NJ, United States of America

Ibc Pharmaceuticals, Inc.

Forward Citations = 1,881

13 inventors:

David M Goldenberg (69 out of 393 patents)

Chien-Hsing Chang (66 out of 140 patents)

Edmund A Rossi (52 out of 77 patents)

4. William John McBride (22 out of 85 patents)

5. Diane Rossi (11 out of 13 patents)

Please report any incorrect information to [email protected]

Loading…